The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Tirzepatide is also the compound in the diabetes drug Mounjaro. Advertising Even before the FDA approval, some doctors have ...

The FDA's approval is based on data from ... those with disabilities are barred from covering weight-loss treatments, though ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20 ... "Zepbound promotes weight loss and has been shown to reduce ...

The FDA approval comes amid growing discussion about the potential uses of weight loss drugs beyond treating obesity and ...

The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...